{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:58:36Z","timestamp":1793321916550,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1001\/jamaoncol.2019.0167","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T12:31:32Z","timestamp":1556800292000},"page":"887","source":"Crossref","is-referenced-by-count":118,"title":["Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration"],"prefix":"10.1001","volume":"5","author":[{"given":"Talal","family":"Hilal","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Bassam","family":"Sonbol","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"},{"name":"Senior Scholar in the Center for Health Care Ethics, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"coi190009r1","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1470-2045(18)30501-1","article-title":"Choice of control group in randomised trials of cancer medicine: are we testing trivialities?","volume":"19","author":"Tao","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi190009r2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/eci.2010.40.issue-2","article-title":"Industry sponsorship and selection of comparators in randomized clinical trials.","volume":"40","author":"Lathyris","year":"2010","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"coi190009r3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.seminhematol.2008.04.010","article-title":"Perfect study, poor evidence: interpretation of biases preceding study design.","volume":"45","author":"Ioannidis","year":"2008","journal-title":"Semin Hematol"},{"issue":"7","key":"coi190009r4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.","volume":"109","author":"Peppercorn","year":"2007","journal-title":"Cancer"},{"issue":"16","key":"coi190009r5","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1056\/NEJMc1600328","article-title":"Ibrutinib for chronic lymphocytic leukemia.","volume":"374","author":"Sharman","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"coi190009r6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma.","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"coi190009r7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma.","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"coi190009r8","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma.","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"coi190009r9","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"coi190009r10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia.","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"coi190009r11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer.","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"coi190009r12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic breast cancer in patients with a germline BRCA mutation.","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"coi190009r13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial.","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10094","key":"coi190009r14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"10072","key":"coi190009r15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"coi190009r17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma.","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"coi190009r18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1470-2045(13)70162-1","article-title":"Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.","volume":"14","author":"Ko","year":"2013","journal-title":"Lancet Oncol"},{"issue":"21","key":"coi190009r19","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1200\/JCO.2005.03.6699","article-title":"Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.","volume":"24","author":"Sweeney","year":"2006","journal-title":"J Clin Oncol"},{"issue":"26","key":"coi190009r20","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer.","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"10043","key":"coi190009r21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"coi190009r22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10022","key":"coi190009r24","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"coi190009r25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"coi190009r26","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma.","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"coi190009r27","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.6004\/jnccn.2011.0095","article-title":"Multiple myeloma.","volume":"9","author":"Anderson","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"9911","key":"coi190009r28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"14","key":"coi190009r29","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/jnci\/86.14.1086","article-title":"Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.","volume":"86","author":"Ajani","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"coi190009r30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s12032-007-0028-6","article-title":"Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.","volume":"24","author":"Albertsson","year":"2007","journal-title":"Med Oncol"},{"issue":"12","key":"coi190009r31","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"coi190009r32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"coi190009r33","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"coi190009r34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/asheducation-2010.1.303","article-title":"Relapsed multiple myeloma.","volume":"2010","author":"Lonial","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"coi190009r35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them.","volume":"16","author":"Pallmann","year":"2018","journal-title":"BMC Med"},{"key":"coi190009r16","unstructured":"US Food and Drug Administration. FDA approves crizotinib capsules. https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm490391.htm. Accessed March 18, 2019."},{"key":"coi190009r23","unstructured":"NelsonR. FDA approves axitinib for advanced renal cell cancer. Medscape. January 27, 2012. https:\/\/www.medscape.com\/viewarticle\/757630. Accessed March 18, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/6\/887\/17676916\/jamaoncology_hilal_2019_oi_190009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T11:01:51Z","timestamp":1561028511000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2019.0167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.0167","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,1]]}}}